Comparative Pharmacology
Head-to-head clinical analysis: ARAVA versus HYDROXYCHLOROQUINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAVA versus HYDROXYCHLOROQUINE.
ARAVA vs Hydroxychloroquine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leflunomide inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, thereby reducing T cell proliferation.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
100 mg orally once daily for 3 days (loading dose), then 20 mg orally once daily (maintenance); if not tolerated, may reduce to 10 mg orally once daily.
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
None Documented
None Documented
Clinical Note
moderateHydroxychloroquine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine."
Clinical Note
moderateHydroxychloroquine + Artemether
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
Clinical Note
moderateHydroxychloroquine + Chloroquine
"The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
Clinical Note
moderateThe terminal elimination half-life of teriflunomide is approximately 18–19 days due to enterohepatic recirculation. This long half-life necessitates a loading dose and may prolong time to steady state (>3 months).
Terminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Following oral administration, ~90% of a dose is excreted in feces (primarily as parent drug and M1 metabolite) and ~10% in urine (M1 metabolite). Biliary excretion is a major route for the active metabolite teriflunomide.
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Category C
Category A/B
DMARD
Antimalarial / DMARD
Hydroxychloroquine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."